Bristol-Myers Squibb Co (BMY) : Capital Advantage added new position in Bristol-Myers Squibb Co during the most recent quarter end. The investment management firm now holds 2,839 shares of Bristol-Myers Squibb Co which is valued at $172,129 , the company said in a statement filed on Aug 10, 2016 with the SEC.Bristol-Myers Squibb Co makes up approximately 0.05% of Capital Advantage’s portfolio.
Other Hedge Funds, Including , Westbourne Investment Advisors reduced its stake in BMY by selling 2,145 shares or 7.34% in the most recent quarter. The Hedge Fund company now holds 27,095 shares of BMY which is valued at $1,642,770. Bristol-Myers Squibb Co makes up approx 1.41% of Westbourne Investment Advisors’s portfolio. Investment Centers Of America Inc sold out all of its stake in BMY during the most recent quarter. The investment firm sold 51,819 shares of BMY which is valued $3,124,686.North Star Asset Management Inc reduced its stake in BMY by selling 800 shares or 5.85% in the most recent quarter. The Hedge Fund company now holds 12,873 shares of BMY which is valued at $963,029. Bristol-Myers Squibb Co makes up approx 0.11% of North Star Asset Management Inc’s portfolio.Foundry Partners reduced its stake in BMY by selling 90,975 shares or 56.76% in the most recent quarter. The Hedge Fund company now holds 69,310 shares of BMY which is valued at $5,307,760. Bristol-Myers Squibb Co makes up approx 0.50% of Foundry Partners’s portfolio.Jacobs Coca reduced its stake in BMY by selling 39 shares or 0.17% in the most recent quarter. The Hedge Fund company now holds 23,384 shares of BMY which is valued at $1,790,747. Bristol-Myers Squibb Co makes up approx 0.41% of Jacobs Coca’s portfolio.
Bristol-Myers Squibb Co opened for trading at $58.74 and hit $59.35 on the upside on Friday, eventually ending the session at $59.29, with a gain of 1.04% or 0.61 points. The heightened volatility saw the trading volume jump to 1,21,34,850 shares. Company has a market cap of $99,065 M.
On the company’s financial health, Bristol-Myers Squibb Co reported $0.69 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.66. The company had revenue of $4881.00 million for the quarter, compared to analysts expectations of $4657.63 million. The company’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.53 EPS.
Investors should note that on Aug 3, 2016, Bristol-Myers Squibb Co announced a cash dividend of $0.3800. The company’s management has announced Oct 5, 2016 as the ex-dividend date and fixed the record date on Oct 7, 2016. The payable date has been fixed on Nov 1, 2016.
Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Bristol-Myers Squibb Co was Downgraded by Berenberg to ” Hold” on Aug 11, 2016. Credit Suisse Downgraded Bristol-Myers Squibb Co on Aug 8, 2016 to ” Neutral”, Price Target of the shares are set at $63.Shares were Reiterated by Deutsche Bank on Aug 8, 2016 to “Hold” and Lowered the Price Target to $ 62 from a previous price target of $68 .
Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.